3–4 Cycles versus 6 Cycles Neoadjuvant Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer: Survival Is Not Determined by the Number of Neoadjuvant Chemotherapy Cycles
Chemotherapy · 2024
DOI: 10.1159/000535755 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemotherapy, 2024. Verfasst von Tugan Bese und 6 weiteren Autor:innen. Beteiligte Einrichtung: Gynecologic Oncology Division, Obstetrics and Gynecology Department, Cerrahpasa Medical Faculty, Istanbul University- Cerrahpasa, Istanbul, Turkey. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Cytoreduction Surgical Procedures. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Introduction
The aim of this study was to compare the disease-free survival (DFS) and overall survival (OS) of patients who underwent interval cytoreductive surgery after 3–4 cycles or 6 cycles of neoadjuvant chemotherapy (NACT) in advanced epithelial ovarian cancer patients.
Methods
Out of 219 patients with advanced epithelial ovarian cancer, 123 patients received 3–4 cycles and 96 patients received 6 cycles of platinum-based NACT. Afterward, laparotomy was performed for interval cytoreductive surgery.
Results
No statistically significant difference was found for DFS and OS of the patients who received 3–4 cycles and those who received 6 cycles of NACT (HR: 1.047, 95.0% CI [0.779–1.407]; p: 0.746 for DFS, and HR: 1.181, 95.0% CI [0.818–1.707]; p: 0.368 for OS). Evaluating 123 patients who received 3–4 cycles of NACT, 87 patients (70.7%) without macroscopic residual tumor after interval cytoreductive surgery had significantly longer DFS and OS compared to 36 patients (29.3%) with any residual tumor (HR: 1.830, 95.0% CI [1.194–2.806]; p: 0.003 for DFS, and HR: 1.946, 95.0% CI [1.166–3.250]; p: 0.009 for OS). 96 patients who received 6 courses of NACT were evaluated; 63 patients (65.6%) without macroscopic residual tumor after interval cytoreductive surgery had significantly longer DFS and OS than 33 patients (34.4%) with any residual tumor (HR: 1.716, 9 5.0% CI [1.092–2.697]; p: 0.010 for DFS, and HR: 1.921, 95.0% CI [1.125–3.282]; p: 0.013 for OS).
Conclusion
In patients with advanced ovarian cancer, there is no significant difference in DFS and OS between 3 and 4 cycles or 6 cycles of NACT. The most important factor determining survival is whether macroscopic residual tumor tissue remains after interval cytoreductive surgery following NACT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Gynecologic Oncology Division, Obstetrics and Gynecology Department, Cerrahpasa Medical Faculty, Istanbul University- Cerrahpasa, Istanbul, Turkey.
- Obstetrics and Gynecology Department, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey.
- Medical Oncology Department, Cerrahpasa Medical Faculty, Istanbul University-Cerrahpasa, Istanbul, Turkey.
Zitieren
APA
Bese, T., Bicer, E., Kayan, B. O., Cebi, S. S., Acikgoz, A. S., Turna, H., & Demirkiran, F. (2024). 3–4 Cycles versus 6 Cycles Neoadjuvant Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer: Survival Is Not Determined by the Number of Neoadjuvant Chemotherapy Cycles. Chemotherapy. https://doi.org/10.1159/000535755
Vancouver
Bese T, Bicer E, Kayan BO, Cebi SS, Acikgoz AS, Turna H, et al. 3–4 Cycles versus 6 Cycles Neoadjuvant Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer: Survival Is Not Determined by the Number of Neoadjuvant Chemotherapy Cycles. Chemotherapy. 2024. doi:10.1159/000535755
BibTeX
@article{Bese2024,
author = {Bese, Tugan and Bicer, Elifnur and Kayan, Basak Ozge and Cebi, Sait Sukru and Acikgoz, Abdullah Serdar and Turna, Hande and Demirkiran, Fuat},
title = {3–4 Cycles versus 6 Cycles Neoadjuvant Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer: Survival Is Not Determined by the Number of Neoadjuvant Chemotherapy Cycles},
journal = {Chemotherapy},
year = {2024},
doi = {10.1159/000535755}
}
EUVIMED